Blood

1. LUSKIN MR, Keating JH, Frost BF, Jaeckle SL, et al
   Venetoclax plus Inotuzumab Ozogamicin for Relapsed and Refractory Acute Lymphoblastic Leukemia.
   Blood. 2026 Sep 25:blood.2026035238. doi: 10.1182/blood.2026035238.
   

   >> Share

   
   
2. AL AMRI R, Bailey N
   NPM1-mutated myeloid neoplasm presenting as chronic eosinophilic leukemia.
   Blood. 2026;148:1754.
   

   >> Share

   
   

   
   BMC Cancer

3. ZHANG C, Luo Q, Wu S, Xu L, et al
   Human single domain antibody-based CAR-T cells targeting BAFF-R demonstrate promising preclinical activity in B-cell malignancies.
   BMC Cancer. 2026;26:1125.
   

   >> Share

   
   

   
   Cancer

4. MOYER P, Leguay T, Jullien M, Huguet F, et al
   Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study.
   Cancer. 2026;132:e70621.
   

   >> Share

   
   

   
   Eur J Haematol

5. TATAR D, Yilmaz E, Ozer NK
   Comment on Sakthivel Et al., "Central Venous Access Device Complications in Children With Leukemia: A Systematic Review and Meta-Analysis".
   Eur J Haematol. 2026 Sep 25. doi: 10.1111/ejh.70325.
   

   >> Share

   
   

   
   Int J Hematol

6. WERNICKE GJ, Enrico AI, Cattaneo M, Bendek Del Prete GE, et al
   Allogeneic transplantation outcomes in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
   Int J Hematol. 2026 Sep 23. doi: 10.1007/s12185-026-04281.
   

   >> Share

   
   
7. NAJIMA Y
   Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.
   Int J Hematol. 2026 Sep 19. doi: 10.1007/s12185-026-04282.
   

   >> Share

   
   

   
   J Natl Cancer Inst

8. ZHANG GQ, Ma C, Yang VB, Shi Q, et al
   Physical activity and molecular residual disease in stage III colon cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702.
   J Natl Cancer Inst. 2026 Sep 24:djag342. doi: 10.1093.
   

   >> Share

   
   

   
   Leuk Res

9. DUTTA R, Schumann C, Cheung E, Zhang TY, et al
   Cladribine and low-dose cytarabine as first salvage after hypomethylating agent and venetoclax in acute myeloid leukemia.
   Leuk Res. 2026;171:108322.
   

   >> Share

   
   
10. LIPTON JH
    Chronic myeloid leukemia is not a familial disease...or maybe it is?
    Leuk Res. 2026;170:108324.
    

    >> Share

    
    

    
    Leukemia

11. DROBNA-SLEDZINSKA M, Buratin A, Roncaglia E, Caregari A, et al
    Systematic profiling of AGO2-associated circRNAs and functional investigation reveal circN4BP2L2 as a survival-promoting regulator in T-ALL.
    Leukemia. 2026;40:2223-2235.
    

    >> Share

    
    
12. KIM AS, Long T, Oldridge DA, Jennings LJ, et al
    Improved inter-lab precision after CML international scale adoption: a 15-year history of BCR::ABL1 proficiency testing.
    Leukemia. 2026;40:2236-2243.
    

    >> Share

    
    
13. HEIBLIG M, Gross Z, Belhabri A, Tauveron-Jalenques U, et al
    Prognostic impact of measurable residual disease in AML patients treated frontline with azacitidine and venetoclax: results from the French VENAURA registry.
    Leukemia. 2026;40:2191-2201.
    

    >> Share

    
    

    
    PLoS One

14. ZATARAH R, Albdour T, Assad A, Budair R, et al
    Bacterial profile and antibiotic susceptibility of bloodstream infections among infants, children, and adolescents undergoing treatment for acute leukemia.
    PLoS One. 2026;21:e0358779.
    

    >> Share

    
    
15. LLORET AVELLA M, Carmo M, Paladio Duran N, Blancher Parcerisa P, et al
    Economic and organizational impact of oral versus intravenous and subcutaneous administration of hypomethylating agents in patients with acute myeloid leukemia not eligible for intensive chemotherapy in Spain.
    PLoS One. 2026;21:e0358426.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share